Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07219121 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

Study acronym: SPARX
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Active, Not Recruiting
    • Study sites: 9 to 8
    v7
  2. Site details revised at 1 of 9 sitesv6
  3. Study sites: 8 to 9v5
  4. Study sites: 5 to 8v4
  5. Study sites: 3 to 5
    • Eligibility criteria expanded, about 14 words
    • Study description expanded, about 12 words
    v3
  6. Secondary endpoints: details revised at 1 of 6 entriesv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the safety and efficacy of sparsentan tablets for the treatment of patients with proteinuria after kidney transplantation with once-daily dosing for 36 weeks.
Trial Details
NCT Number NCT07219121
Lead Sponsor Travere Therapeutics, Inc.
Conditions
(from sponsor)		 Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Transplant
Related terms Glomerulosclerosis, Focal Segmental, Kidney Diseases, Proteinuria
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov